Kevin D'rummo, MD
Radiation Oncology · Beachwood, OHNPI 1437512746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations.
Across 156 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$306
- Merck$261
- Johnson & Johnson$231
- Lilly USA, LLC$212
- Incyte Corporation$184
- Regeneron Healthcare Solutions, Inc.$127
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,015100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $306 |
| Merck | 14 | $261 |
| Johnson & Johnson | 12 | $231 |
| Lilly USA, LLC | 10 | $212 |
| Incyte Corporation | 11 | $184 |
| Regeneron Healthcare Solutions, Inc. | 5 | $127 |
| Pfizer | 6 | $123 |
| AbbVie | 5 | $119 |
| Genentech USA, Inc. | 7 | $112 |
| AstraZeneca(2 entities) | 5 | $101 |
| AVEO Pharmaceuticals, Inc. | 5 | $86 |
| Boehringer Ingelheim | 5 | $86 |
| Sanofi | 4 | $82 |
| Seagen Inc. | 5 | $81 |
| Bayer | 4 | $74 |
| Eisai Inc. | 3 | $62 |
| Ipsen Biopharmaceuticals, Inc | 4 | $62 |
| Blueprint Medicines Corporation | 3 | $60 |
| Taiho Oncology, Inc. | 3 | $55 |
| Tempus AI, Inc | 2 | $48 |
| EUSA Pharma (US) LLC | 2 | $45 |
| Beone Medicines USA, Inc. | 2 | $42 |
| Genmab U.S., Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| ADC Therapeutics America, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| EMD Serono, Inc. | 2 | $33 |
| Adaptive Biotechnologies Corporation | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Telix Pharmaceuticals | 1 | $24 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Caris MPI, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Morphosys, US Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
How this compares
$3,015 in reported general payments places this provider in the 85th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 16 | $306 |
| Tamsulosin Hcl | 24 | $279 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $181 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Beachwood
- Steven KurtzmanGarfield Heights$833K
- Joshua PalmerColumbus$123K
- Norleena PoynterSandusky$90K
- Daniel SprattCleveland$86K
- Shlomo KoyfmanCleveland$72K
- Gerald SokolCleveland$61K
- Peter FriedFairfield$45K
- Rahul TendulkarCleveland$26K
- Sujith BaligaColumbus$26K
- Anthony ParavatiKettering$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.